baxdrostat

baxdrostat is an investigational **oral small-molecule aldosterone synthase inhibitor** being developed for cardiorenal indications, principally hard-to-control, resistant, and uncontrolled hypertension, with additional development in primary aldosteronism and chronic kidney disease. Originally developed by CinCor Pharma and later acquired by AstraZeneca, baxdrostat is designed to selectively inhibit **aldosterone synthase** and thereby reduce aldosterone production while aiming to avoid clinically meaningful inhibition of cortisol synthesis. Public sources identify it as a potential first-in-class therapy in this mechanism class, with Phase 2 data in treatment-resistant hypertension, Phase 3 programs in hypertension and primary aldosteronism, and an FDA-accepted NDA under Priority Review in the US for hard-to-control hypertension.

Other names

baxdrostatRO6836191RO-6836191RO 6836191CIN-107CIN107CIN 107